Company Overview
Clene Inc. operates as a clinical-stage pharmaceutical entity dedicated to the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics, with its primary focus on the lead drug candidate CNM-Au8 which is currently being studied in various clinical trials including a completed Phase 2. The company functions within the Consumer Defensive sector and the Packaged Foods industry, classifications that suggest a business model potentially centered on consumer-facing health products or therapeutic solutions, though its specific operational activities remain defined by its nanotechnology research focus. In terms of scale, Clene Inc. holds a market capitalization of $55.48M, reports trailing twelve-month revenue of $200,000, and employs 76 individuals. These financial figures indicate a small-cap organization with extremely limited revenue generation relative to its market valuation, suggesting the company exists primarily in a pre-commercial or early-stage development phase where valuation is driven by pipeline potential rather than current profitability or established market share.
Financial Health
The company reports trailing twelve-month revenue of $200,000, a net income of $-26,173,000, and EBITDA of $-21,588,000, revealing a substantial gap between top-line sales and bottom-line results that indicates a heavy cost structure likely dominated by research and development expenses or clinical trial costs. The firm generates free cash flow of $-10,136,125, which signifies a negative cash conversion where operational cash outflows exceed inflows, thereby limiting financial flexibility and necessitating external capital raises to sustain operations. Margin analysis shows a gross margin of 78.5%, which implies high efficiency in production or low cost of goods sold relative to sales, contrasted sharply by an operating margin of -9733.8% and a profit margin of 0.0%, indicating that operational expenses and other costs significantly erode profitability before reaching the net income line. Regarding liquidity and leverage, Clene Inc. holds $5.19M in cash against $21.67M in debt, while the debt-to-equity ratio is listed as N/A, suggesting a balance sheet that is heavily leveraged relative to its equity base and cash reserves. The current ratio stands at 0.83, indicating that current assets are insufficient to cover current liabilities, which points to potential short-term liquidity challenges. Furthermore, the return on equity is N/A and return on assets is -63.5%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
Valuation Assessment
Valuation metrics for Clene Inc. display significant distortions due to losses, with a trailing P/E ratio of N/A and a forward P/E of -3.24, implying that the market is not pricing the stock based on historical earnings but rather on speculative expectations of future earnings recovery or turnaround. The price-to-book ratio is recorded at -2.91, a negative figure that indicates the company's market value is below its book value, often seen in distressed or speculative situations where market sentiment does not align with the recorded net asset value. Alternative valuation multiples such as the price-to-sales ratio of 277.38 and an EV/EBITDA of -3.33 suggest that investors are willing to pay a substantial multiple relative to sales despite the lack of profitability, highlighting a valuation driven by the potential of the CSN therapeutics pipeline rather than current financial performance. The stock has traded within a 52-week range with a high of $13.50 and a low of $2.28, meaning the current price sits at the lower end of this historical spectrum, reflecting the negative sentiment associated with its financial losses and high valuation multiples. The beta of 0.62 indicates that the stock exhibits lower price volatility relative to the broader market, moving less than half as much as the market index on average, which may offer some stability for long-term holders despite the underlying financial risks.
Growth & Income
Revenue growth year-over-year is -15.4%, while earnings growth year-over-year is N/A, indicating that the company is currently contracting in terms of sales and has not yet achieved positive earnings growth to compare trajectories against. As a non-dividend payer, Clene Inc. does not distribute a dividend yield or utilize a payout ratio, meaning the company retains all available cash and reinvests earnings directly into growth initiatives such as clinical trials and drug development rather than returning capital to shareholders. The overall growth and income profile is characterized by negative revenue expansion and zero income distribution, reflecting a typical early-stage biopharmaceutical or clinical-stage pharmaceutical company that prioritizes capital allocation toward R&D over immediate financial returns or shareholder payouts. This strategic approach is consistent with firms in the discovery and development phase of novel clean-surfaced nanotechnology therapeutics, where the primary objective is advancing the lead drug candidate CNM-Au8 through clinical milestones rather than generating immediate cash flow or dividends.